Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | PLOD2 | O00469 | 3/20 | 0.49 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.49 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1255786 | 0.77 | TSHR (0.48) | ALDH1A1HPGDL3MBTL1MEN1KMT2A | |
| SCHEMBL1515846 | 0.71 | ALDH1A1 (0.66) | ALDH1A1PLOD2PLOD3PLOD1CYP1A2 | |
| SCHEMBL4519339 | 0.70 | PTGS1 (0.40) | KMT2AHTTSMN1; SMN2GAATSHR | |
| SCHEMBL1157353 | 0.68 | ALDH1A1 (0.66) | ALDH1A1PLOD2PLOD3PLOD1CYP1A2 | |
| SCHEMBL11644624 | 0.67 | MAPK1 (0.50) | ALDH1A1PLOD2PLOD3PLOD1CYP1A2 | |
| SCHEMBL9195700 | 0.67 | ALDH1A1 (0.77) | ALDH1A1PLOD2PLOD3PLOD1CYP1A2 | |
| SCHEMBL8053052 | 0.67 | PLOD2 (1.00) | ALDH1A1PLOD2PLOD3PLOD1CYP1A2 | |
| SCHEMBL11780792 | 0.66 | PTGS1 (0.42) | ALDH1A1HPGDSMN1; SMN2MAPTRAB9A | |
| SCHEMBL4652501 | 0.66 | DPP4 (0.47) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5634176 | 0.65 | MAPK14 (0.49) | MEN1KMT2ANAPRTSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3002283-B1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-06-14 | — | — | EP | disclosed |
| EP-3002283-A1 | THIAZOLE DERIVATIVES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-1700856-B1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-8889718-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20130267509-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8420827-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20110105486-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7880013-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1700856-A1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267509-A1 | THIAZOLE DERIVATIVES | THRA, CHD8, CYP2C8 | ALDH1A1 1344/4885PLOD2 3413/4885PLOD3 3531/4885 |
| US-20110105486-A1 | THIAZOLE DERIVATIVES | CHD8, CYP2C8, THRA | ALDH1A1 769/4885PLOD2 2592/4885PLOD3 3854/4885 |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | ALDH1A1 1290/4885PLOD2 4469/4885PLOD3 4297/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | ALDH1A1 2843/4885PLOD2 4638/4885PLOD3 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.